Skip to content

Corcept Therapeutics

US · CORT #1285 by market cap Listed 1970
63.62 -1.36 -2.09%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Company notice
    Columbia Banking System | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer O'HAVER CORT L
    SEC · 2025/3/15
  • Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
    Market Newswire · 2026/10/26
  • Rating change
    Truist Financial Initiates Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $164
    Market Newswire · 2026/8/18
  • Rating change
    Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $88
    Market Newswire · 2026/6/1
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Vertex Pharmaceuticals (VRTX) and Corcept Therapeutics (CORT)
    TipRanks · 2026/10/15
  • Rating change
    H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $95
    Market Newswire · 2026/6/2
  • Rating change
    H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165
    Market Newswire · 2026/7/30
  • Company notice
    Columbia Banking System | 4: Statement of changes in beneficial ownership of securities-Officer O'HAVER CORT L
    SEC · 2024/4/24
  • CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $161
    Market Newswire · 2026/11/5
  • Rating change
    CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $161
    Market Newswire · 2026/7/29
  • GUIDANCE: (CORT) Corcept Therapeutics Reiterates 2026 Revenue Guidance of $1.1B-$1.2B, Vs. FactSet Est of $1.15B
    MT Newswires · 2026/11/4
  • H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
    Market Newswire · 2026/11/6
  • Rating change
    CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135
    Market Newswire · 2026/7/9
  • Company notice
    Columbia Banking System | 4: Statement of changes in beneficial ownership of securities-Officer O'HAVER CORT L
    SEC · 2025/2/27
  • Company notice
    Columbia Banking System | 4: Statement of changes in beneficial ownership of securities-Officer O'HAVER CORT L
    SEC · 2025/3/5
  • Rating change
    Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165
    Market Newswire · 2026/7/30
  • Rating change
    Wolfe Research Downgrades Corcept Therapeutics(CORT.US) to Sell Rating, Announces Target Price $50
    Market Newswire · 2026/7/27
  • Company notice
    Columbia Banking System | 4: Statement of changes in beneficial ownership of securities-Officer O'HAVER CORT L
    SEC · 2025/2/19
  • Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $173
    Market Newswire · 2026/11/4
  • Rating change
    Wolfe Research Maintains Corcept Therapeutics(CORT.US) With Sell Rating, Maintains Target Price $50
    Market Newswire · 2026/7/30
  • Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common Stocks
    Market Newswire · 2026/9/15
  • Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
    Market Newswire · 2026/10/19
  • Rating change
    CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/5/4
  • Rating change
    CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $135
    Market Newswire · 2026/5/28
  • Rating change
    H.C. Wainwright Keeps Their Buy Rating on Corcept Therapeutics (CORT)
    TipRanks · 2026/6/1

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Corcept Therapeutics discussion 0 comments

Add a comment